Senseonics rises on FDA nod for continuous glucose monitoring system

Senseonics Holdings

17/09/2024 15:31

** Shares of medtech firm Senseonics Holdings  SENS.A  rise
12.7% to 44 cents 
    ** Co and Ascensia Diabetes Care announce that the U.S. FDA 
has cleared its continuous glucose monitoring system (CGM)
called Eversense 365, that can be worn for one year 
    ** The CGM is for people with Type 1 and Type 2 diabetes
aged 18 years and older
     ** The device has a sensor that can be worn for a year,
compared to every 10-14 days with short-term CGM systems, co
says  
    ** Expects to initiate the US launch of Eversense 365 US in
the fourth quarter of 2024
    ** Including session moves, stock down 23.9% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))